Action and reaction: The biological response to sirna and its delivery vehicles

Molecular Therapy

Volumn 20, Issue 3, 2012, Pages 513-524

  Kanasty, Rosemary L ^a,b   Whitehead, Kathryn A ^b   Vegas, Arturo J ^b   Anderson, Daniel G ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGONAUTE 2 PROTEIN; DRUG CARRIER; LIPID; MACROGOL; NANOPARTICLE; POLYETHYLENEIMINE; SMALL INTERFERING RNA;

ADVERSE OUTCOME; CHEMICAL MODIFICATION; CYTOTOXICITY; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; DRUG URINE LEVEL; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VIVO STUDY; INNATE IMMUNITY; PARTICLE SIZE; REVIEW; RNA INTERFERENCE; RNA SEQUENCE; RNA STRUCTURE; SINGLE DRUG DOSE; TREATMENT RESPONSE;

EID: 84863418151     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.294     Document Type: Review

References (170)

1. Elbashir, SM, Harborth, J, Lendeckel, W, Yalcin, A, Weber, K and Tuschl, T (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498. (Pubitemid 32494397)
2. Whitehead, KA, Langer, R and Anderson, DG (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8: 129-138.
3. Pei, Y and Tuschl, T (2006). On the art of identifying effective and specific siRNAs. Nat Methods 3: 670-676. (Pubitemid 44275732)
4. Reynolds, A, Leake, D, Boese, Q, Scaringe, S, Marshall, WS and Khvorova, A (2004). Rational siRNA design for RNA interference. Nat Biotechnol 22: 326-330. (Pubitemid 38295766)
5. Lu, ZJ and Mathews, DH (2008). OligoWalk: an online siRNA design tool utilizing hybridization thermodynamics. Nucleic Acids Res 36(Web Server issue): W104-W108.
6. Schwarz, DS, Hutvágner, G, Du, T, Xu, Z, Aronin, N and Zamore, PD (2003). Asymmetry in the assembly of the RNAi enzyme complex. Cell 115: 199-208. (Pubitemid 37329583)
7. Tafer, H, Ameres, SL, Obernosterer, G, Gebeshuber, CA, Schroeder, R, Martinez, J et al. (2008). The impact of target site accessibility on the design of effective siRNAs. Nat Biotechnol 26: 578-583. (Pubitemid 351668044)
8. Nykänen, A, Haley, B and Zamore, PD (2001). ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107: 309-321. (Pubitemid 33049975)
9. Vaish, N, Chen, F, Seth, S, Fosnaugh, K, Liu, Y, Adami, R et al. (2011). Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs. Nucleic Acids Res 39: 1823-1832.
10. Bramsen, JB, Pakula, MM, Hansen, TB, Bus, C, Langkjær, N, Odadzic, D et al. (2010). A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res 38: 5761-5773.
11. Laursen, MB, Pakula, MM, Gao, S, Fluiter, K, Mook, OR, Baas, F et al. (2010). Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol Biosyst 6: 862-870.
12. Weitzer, S and Martinez, J (2007). The human RNA kinase hClp1 is active on 3' transfer RNA exons and short interfering RNAs. Nature 447: 222-226. (Pubitemid 46763082)
13. Chen, PY, Weinmann, L, Gaidatzis, D, Pei, Y, Zavolan, M, Tuschl, T et al. (2008). Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 14: 263-274. (Pubitemid 351171587)
14. Zuhorn, IS, Engberts, JB and Hoekstra, D (2007). Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur Biophys J 36: 349-362. (Pubitemid 46626209)
15. Chiu, YL and Rana, TM (2003). siRNA function in RNAi: a chemical modification analysis. RNA 9: 1034-1048. (Pubitemid 37093614)
16. Khvorova, A, Reynolds, A and Jayasena, SD (2003). Functional siRNAs and miRNAs exhibit strand bias. Cell 115: 209-216. (Pubitemid 37329584)
17. Ameres, SL, Martinez, J and Schroeder, R (2007). Molecular basis for target RNA recognition and cleavage by human RISC. Cell 130: 101-112. (Pubitemid 47031315)
18. Brown, KM, Chu, CY and Rana, TM (2005). Target accessibility dictates the potency of human RISC. Nat Struct Mol Biol 12: 469-470. (Pubitemid 43085910)
19. Köberle, C, Kaufmann, SH and Patzel, V (2006). Selecting effective siRNAs based on guide RNA structure. Nat Protoc 1: 1832-1839. (Pubitemid 46773303)
20. Patzel, V, Rutz, S, Dietrich, I, Köberle, C, Scheffold, A and Kaufmann, SH (2005). Design of siRNAs producing unstructured guide-RNAs results in improved RNA interference efficiency. Nat Biotechnol 23: 1440-1444. (Pubitemid 41679398)
21. Huesken, D, Lange, J, Mickanin, C, Weiler, J, Asselbergs, F, Warner, J et al. (2005). Design of a genome-wide siRNA library using an artificial neural network. Nat Biotechnol 23: 995-1001. (Pubitemid 41114034)
22. Jackson, AL and Linsley, PS (2010). Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9: 57-67.
23. Whitehead, KA, Dahlman, JE, Langer, RS and Anderson, DG (2011). Silencing or stimulation? siRNA delivery and the immune system. Annu Rev Chem Biomol Eng 2: 77-96.
24. Fève, B and Bastard, JP (2009). The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 5: 305-311.
25. García-Sastre, A and Biron, CA (2006). Type 1 interferons and the virus-host relationship: a lesson in détente. Science 312: 879-882. (Pubitemid 43727313)
26. Locksley, RM, Killeen, N and Lenardo, MJ (2001). The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501. (Pubitemid 32201945)
27. Akira, S, Uematsu, S and Takeuchi, O (2006). Pathogen recognition and innate immunity. Cell 124: 783-801. (Pubitemid 43261452)
28. Marques, JT, Devosse, T, Wang, D, Zamanian-Daryoush, M, Serbinowski, P, Hartmann, R et al. (2006). A structural basis for discriminating between self and nonself doublestranded RNAs in mammalian cells. Nat Biotechnol 24: 559-565.
29. Takeuchi, O and Akira, S (2010). Pattern recognition receptors and inflammation. Cell 140: 805-820.
30. Akira, S, Takeda, K and Kaisho, T (2001). Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2: 675-680. (Pubitemid 32747155)
31. Kawai, T and Akira, S (2010). The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384.
32. Robbins, M, Judge, A and MacLachlan, I (2009). siRNA and innate immunity. Oligonucleotides 19: 89-102.
33. Meurs, E, Chong, K, Galabru, J, Thomas, NS, Kerr, IM, Williams, BR et al. (1990). Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 62: 379-390.
34. Kato, H, Sato, S, Yoneyama, M, Yamamoto, M, Uematsu, S, Matsui, K et al. (2005). Cell type-specific involvement of RIG-I in antiviral response. Immunity 23: 19-28. (Pubitemid 41019654)
35. Judge, AD, Sood, V, Shaw, JR, Fang, D, McClintock, K and MacLachlan, I (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23: 457-462. (Pubitemid 41724921)
36. Heil, F, Hemmi, H, Hochrein, H, Ampenberger, F, Kirschning, C, Akira, S et al. (2004). Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303: 1526-1529. (Pubitemid 38314424)
37. Hornung, V, Ellegast, J, Kim, S, Brzózka, K, Jung, A, Kato, H et al. (2006). 5'-Triphosphate RNA is the ligand for RIG-I. Science 314: 994-997.
38. Pichlmair, A, Schulz, O, Tan, CP, Näslund, TI, Liljeström, P, Weber, F et al. (2006). RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 314: 997-1001. (Pubitemid 44749946)
39. Kim, DH, Longo, M, Han, Y, Lundberg, P, Cantin, E and Rossi, JJ (2004). Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 22: 321-325. (Pubitemid 38295765)
40. Elmén, J, Thonberg, H, Ljungberg, K, Frieden, M, Westergaard, M, Xu, Y et al. (2005). Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 33: 439-447. (Pubitemid 40276964)
41. Langkjaer, N, Pasternak, A and Wengel, J (2009). UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorg Med Chem 17: 5420-5425.
42. Morrissey, DV, Lockridge, JA, Shaw, L, Blanchard, K, Jensen, K, Breen, W et al. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23: 1002-1007. (Pubitemid 41114035)
43. Heidel, JD, Hu, S, Liu, XF, Triche, TJ and Davis, ME (2004). Lack of interferon response in animals to naked siRNAs. Nat Biotechnol 22: 1579-1582. (Pubitemid 40039462)
44. Kornek, M, Lukacs-Kornek, V, Limmer, A, Raskopf, E, Becker, U, Klöckner, M et al. (2008). 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)-formulated, immunestimulatory vascular endothelial growth factor a small interfering RNA (siRNA) increases antitumoral efficacy in murine orthotopic hepatocellular carcinoma with liver fibrosis. Mol Med 14: 365-373.
45. Cubillos-Ruiz, JR, Engle, X, Scarlett, UK, Martinez, D, Barber, A, Elgueta, R et al. (2009). Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 119: 2231-2244.
46. Akinc, A, Thomas, M, Klibanov, AM and Langer, R (2005). Exploring polyethyleniminemediated DNA transfection and the proton sponge hypothesis. J Gene Med 7: 657-663. (Pubitemid 40744532)
47. Nguyen, DN, Chen, SC, Lu, J, Goldberg, M, Kim, P, Sprague, A et al. (2009). Drug delivery-mediated control of RNA immunostimulation. Mol Ther 17: 1555-1562.
48. Holen, T, Moe, SE, Sørbø, JG, Meza, TJ, Ottersen, OP and Klungland, A (2005). Tolerated wobble mutations in siRNAs decrease specificity, but can enhance activity in vivo. Nucleic Acids Res 33: 4704-4710. (Pubitemid 41418872)
49. Jackson, AL, Bartz, SR, Schelter, J, Kobayashi, SV, Burchard, J, Mao, M et al. (2003). Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21: 635-637. (Pubitemid 36638089)
50. Fedorov, Y, Anderson, EM, Birmingham, A, Reynolds, A, Karpilow, J, Robinson, K et al. (2006). Off-target effects by siRNA can induce toxic phenotype. RNA 12: 1188-1196. (Pubitemid 43990544)
51. Lai, EC (2002). Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 30: 363-364.
52. Doench, JG and Sharp, PA (2004). Specificity of microRNA target selection in translational repression. Genes Dev 18: 504-511. (Pubitemid 38372808)
53. Wu, L, Fan, J and Belasco, JG (2006). MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci USA 103: 4034-4039.
54. Farh, KK, Grimson, A, Jan, C, Lewis, BP, Johnston, WK, Lim, LP et al. (2005). The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 310: 1817-1821. (Pubitemid 41814382)
55. Krek, A, Grün, D, Poy, MN, Wolf, R, Rosenberg, L, Epstein, EJ et al. (2005). Combinatorial microRNA target predictions. Nat Genet 37: 495-500. (Pubitemid 40617277)
56. Lewis, BP, Shih, IH, Jones-Rhoades, MW, Bartel, DP and Burge, CB (2003). Prediction of mammalian microRNA targets. Cell 115: 787-798. (Pubitemid 38058492)
57. Lim, LP, Lau, NC, Garrett-Engele, P, Grimson, A, Schelter, JM, Castle, J et al. (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773. (Pubitemid 40292988)
58. Xie, X, Lu, J, Kulbokas, EJ, Golub, TR, Mootha, V, Lindblad-Toh, K et al. (2005). Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature 434: 338-345. (Pubitemid 40469170)
59. Semizarov, D, Frost, L, Sarthy, A, Kroeger, P, Halbert, DN and Fesik, SW (2003). Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci USA 100: 6347-6352. (Pubitemid 36666584)
60. Jackson, AL, Burchard, J, Leake, D, Reynolds, A, Schelter, J, Guo, J et al. (2006). Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12: 1197-1205. (Pubitemid 43990545)
61. Birmingham, A, Anderson, EM, Reynolds, A, Ilsley-Tyree, D, Leake, D, Fedorov, Y et al. (2006). 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 3: 199-204.
62. Boese, Q, Leake, D, Reynolds, A, Read, S, Scaringe, SA, Marshall, WS et al. (2005). Mechanistic insights aid computational short interfering RNA design. Meth Enzymol 392: 73-96. (Pubitemid 40092509)
63. Naito, Y, Yoshimura, J, Morishita, S and Ui-Tei, K (2009). siDirect 2.0: updated software for designing functional siRNA with reduced seed-dependent off-target effect. BMC Bioinformatics 10: 392.
64. Petri, S, Dueck, A, Lehmann, G, Putz, N, Rüdel, S, Kremmer, E et al. (2011). Increased siRNA duplex stability correlates with reduced off-target and elevated on-target effects. RNA 17: 737-749.
65. Grimm, D, Streetz, KL, Jopling, CL, Storm, TA, Pandey, K, Davis, CR et al. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541. (Pubitemid 44050158)
66. Castanotto, D, Sakurai, K, Lingeman, R, Li, H, Shively, L, Aagaard, L et al. (2007). Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res 35: 5154-5164. (Pubitemid 47394199)
67. Vickers, TA, Lima, WF, Nichols, JG and Crooke, ST (2007). Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells. Nucleic Acids Res 35: 6598-6610. (Pubitemid 350111625)
68. Koller, E, Propp, S, Murray, H, Lima, W, Bhat, B, Prakash, TP et al. (2006). Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res 34: 4467-4476. (Pubitemid 44567046)
69. Khan, AA, Betel, D, Miller, ML, Sander, C, Leslie, CS and Marks, DS (2009). Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol 27: 549-555.
70. Yi, R, Doehle, BP, Qin, Y, Macara, IG and Cullen, BR (2005). Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. RNA 11: 220-226. (Pubitemid 40165636)
71. Hutvágner, G, Simard, MJ, Mello, CC and Zamore, PD (2004). Sequence-specific inhibition of small RNA function. PLoS Biol 2: E98.
72. Grimm, D, Wang, L, Lee, JS, Schürmann, N, Gu, S, Börner, K et al. (2010). Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest 120: 3106-3119.
73. Giering, JC, Grimm, D, Storm, TA and Kay, MA (2008). Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 16: 1630-1636.
74. Akinc, A, Zumbuehl, A, Goldberg, M, Leshchiner, ES, Busini, V, Hossain, N et al. (2008). A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26: 561-569. (Pubitemid 351668042)
75. Zimmermann, TS, Lee, AC, Akinc, A, Bramlage, B, Bumcrot, D, Fedoruk, MN et al. (2006). RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114.
76. Love, KT, Mahon, KP, Levins, CG, Whitehead, KA, Querbes, W, Dorkin, JR et al. (2010). Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107: 1864-1869.
77. Lv, H, Zhang, S, Wang, B, Cui, S and Yan, J (2006). Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 114: 100-109. (Pubitemid 44128621)
78. Kedmi, R, Ben-Arie, N and Peer, D (2010). The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 31: 6867-6875.
79. Soenen, SJ, Brisson, AR and De Cuyper, M (2009). Addressing the problem of cationic lipid-mediated toxicity: the magnetoliposome model. Biomaterials 30: 3691-3701.
80. Dokka, S, Toledo, D, Shi, X, Castranova, V and Rojanasakul, Y (2000). Oxygen radicalmediated pulmonary toxicity induced by some cationic liposomes. Pharm Res 17: 521-525. (Pubitemid 30416388)
81. Bottega, R and Epand, RM (1992). Inhibition of protein kinase C by cationic amphiphiles. Biochemistry 31: 9025-9030.
82. Solodin, I, Brown, CS, Bruno, MS, Chow, CY, Jang, EH, Debs, RJ et al. (1995). A novel series of amphiphilic imidazolinium compounds for in vitro and in vivo gene delivery. Biochemistry 34: 13537-13544.
83. van der Woude, I, Wagenaar, A, Meekel, AAP, ter Beest, MBA, Ruiters, MHJ, Engberts, Jan BFN et al. (1997). Novel pyridinium surfactants for efficient, nontoxic in vitro gene delivery. Proc Natl Acad Sci USA 94: 1160-1165. (Pubitemid 27087821)
84. Leventis, R and Silvius, JR (1990). Interactions of mammalian cells with lipid dispersions containing novel metabolizable cationic amphiphiles. Biochim Biophys Acta 1023: 124-132. (Pubitemid 20100770)
85. Semple, SC, Akinc, A, Chen, J, Sandhu, AP, Mui, BL, Cho, CK et al. (2010). Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28: 172-176.
86. Xu, Y, Hui, SW, Frederik, P and Szoka, FC Jr (1999). Physicochemical characterization and purification of cationic lipoplexes. Biophys J 77: 341-353. (Pubitemid 29305233)
87. Moghimi, SM, Symonds, P, Murray, JC, Hunter, AC, Debska, G and Szewczyk, A (2005). A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther 11: 990-995. (Pubitemid 40724119)
88. Malek, A, Merkel, O, Fink, L, Czubayko, F, Kissel, T and Aigner, A (2009). In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol Appl Pharmacol 236: 97-108.
89. Beyerle, A, Irmler, M, Beckers, J, Kissel, T and Stoeger, T (2010). Toxicity pathway focused gene expression profiling of PEI-based polymers for pulmonary applications. Mol Pharm 7: 727-737.
90. Merkel, OM, Beyerle, A, Beckmann, BM, Zheng, M, Hartmann, RK, Stöger, T et al. (2011). Polymer-related off-target effects in non-viral siRNA delivery. Biomaterials 32: 2388-2398.
91. Omidi, Y, Hollins, AJ, Benboubetra, M, Drayton, R, Benter, IF and Akhtar, S (2003). Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectinand oligofectamine-induced gene expression changes in human epithelial cells. J Drug Target 11: 311-323. (Pubitemid 38081335)
92. Akhtar, S and Benter, I (2007). Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev 59: 164-182. (Pubitemid 46773052)
93. Kircheis, R, Wightman, L and Wagner, E (2001). Design and gene delivery activity of modified polyethylenimines. Adv Drug Deliv Rev 53: 341-358. (Pubitemid 34024914)
94. Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178. (Pubitemid 39545841)
95. Layzer, JM, McCaffrey, AP, Tanner, AK, Huang, Z, Kay, MA and Sullenger, BA (2004). In vivo activity of nuclease-resistant siRNAs. RNA 10: 766-771. (Pubitemid 38529739)
96. Buyens, K, Demeester, J, De Smedt, SS and Sanders, NN (2009). Elucidating the encapsulation of short interfering RNA in PEGylated cationic liposomes. Langmuir 25: 4886-4891.
97. Akinc, A, Goldberg, M, Qin, J, Dorkin, JR, Gamba-Vitalo, C, Maier, M et al. (2009). Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther 17: 872-879.
98. Deleavey, GF, Watts, JK and Damha, MJ (2009). Chemical modification of siRNA. Curr Protoc Nucleic Acid Chem Chapter 16: Unit 16.3.
99. Turner, JJ, Jones, SW, Moschos, SA, Lindsay, MA and Gait, MJ (2007). MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol Biosyst 3: 43-50. (Pubitemid 44924958)
100. Raines, RT (1998). Ribonuclease A. Chem Rev 98: 1045-1066.
101. Mook, OR, Baas, F, de Wissel, MB and Fluiter, K (2007). Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther 6: 833-843. (Pubitemid 46554553)
102. Braasch, DA, Paroo, Z, Constantinescu, A, Ren, G, Oz, OK, Mason, RP et al. (2004). Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett 14: 1139-1143. (Pubitemid 38229843)
103. Gao, S, Dagnaes-Hansen, F, Nielsen, EJ, Wengel, J, Besenbacher, F, Howard, KA et al. (2009). The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther 17: 1225-1233.
104. Wolfrum, C, Shi, S, Jayaprakash, KN, Jayaraman, M, Wang, G, Pandey, RK et al. (2007). Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25: 1149-1157. (Pubitemid 47538115)
105. Akinc, A, Querbes, W, De, S, Qin, J, Frank-Kamenetsky, M, Jayaprakash, KN et al. (2010). Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18: 1357-1364.
106. Alexis, F, Pridgen, E, Molnar, LK and Farokhzad, OC (2008). Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5: 505-515.
107. Romberg, B, Hennink, WE and Storm, G (2008). Sheddable coatings for longcirculating nanoparticles. Pharm Res 25: 55-71.
108. Bazile, D, Prud'homme, C, Bassoullet, MT, Marlard, M, Spenlehauer, G and Veillard, M (1995). Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci 84: 493-498.
109. Peracchia, MT, Harnisch, S, Pinto-Alphandary, H, Gulik, A, Dedieu, JC, Desmaële, D et al. (1999). Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials 20: 1269-1275. (Pubitemid 29281378)
110. Aird, WC (2007). Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 100: 158-173. (Pubitemid 46208717)
111. Minshall, RD, Tiruppathi, C, Vogel, SM and Malik, AB (2002). Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function. Histochem Cell Biol 117: 105-112. (Pubitemid 34185616)
112. Jain, RK and Stylianopoulos, T (2010). Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7: 653-664.
113. Aird, WC (2007). Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res 100: 174-190. (Pubitemid 46208718)
114. Wisse, E, Jacobs, F, Topal, B, Frederik, P and De Geest, B (2008). The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther 15: 1193-1199.
115. Merkel, OM, Librizzi, D, Pfestroff, A, Schurrat, T, Buyens, K, Sanders, NN et al. (2009). Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. J Control Release 138: 148-159.
116. Frank-Kamenetsky, M, Grefhorst, A, Anderson, NN, Racie, TS, Bramlage, B, Akinc, A et al. (2008). Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 105: 11915-11920.
117. Shi, B, Keough, E, Matter, A, Leander, K, Young, S, Carlini, E et al. (2011). Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery. J Histochem Cytochem 59: 727-740.
118. Schroeder, A, Levins, CG, Cortez, C, Langer, R and Anderson, DG (2010). Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 267: 9-21.
119. Fukumura, D, Duda, DG, Munn, LL and Jain, RK (2010). Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 17: 206-225.
120. Jain, RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62. (Pubitemid 40093472)
121. Vakoc, BJ, Lanning, RM, Tyrrell, JA, Padera, TP, Bartlett, LA, Stylianopoulos, T et al. (2009). Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med 15: 1219-1223.
122. Roberts, WG and Palade, GE (1997). Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 57: 765-772. (Pubitemid 27085664)
123. Hashizume, H, Baluk, P, Morikawa, S, McLean, JW, Thurston, G, Roberge, S et al. (2000). Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156: 1363-1380. (Pubitemid 30660013)
124. Hobbs, SK, Monsky, WL, Yuan, F, Roberts, WG, Griffith, L, Torchilin, VP et al. (1998). Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 95: 4607-4612. (Pubitemid 28207960)
125. Yuan, F, Salehi, HA, Boucher, Y, Vasthare, US, Tuma, RF and Jain, RK (1994). Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 54: 4564-4568. (Pubitemid 24276471)
126. Padera, TP, Kadambi, A, di Tomaso, E, Carreira, CM, Brown, EB, Boucher, Y et al. (2002). Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296: 1883-1886. (Pubitemid 34596277)
127. Leu, AJ, Berk, DA, Lymboussaki, A, Alitalo, K and Jain, RK (2000). Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 60: 4324-4327. (Pubitemid 32103603)
128. Maeda, H, Wu, J, Sawa, T, Matsumura, Y and Hori, K (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65: 271-284. (Pubitemid 30122932)
129. Maeda, H (2010). Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 21: 797-802.
130. Wong, CC, Gilkes, DM, Zhang, H, Chen, J, Wei, H, Chaturvedi, P et al. (2011). Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci USA 108: 16369-16374.
131. Leuschner, F, Dutta, P, Gorbatov, R, Novobrantseva, TI, Donahoe, JS, Courties, G et al. (2011). Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 29: 1005-1010.
132. Caron, E and Hall, A (1998). Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. Science 282: 1717-1721. (Pubitemid 28549289)
133. Groves, E, Dart, AE, Covarelli, V and Caron, E (2008). Molecular mechanisms of phagocytic uptake in mammalian cells. Cell Mol Life Sci 65: 1957-1976.
134. Swanson, JA and Baer, SC (1995). Phagocytosis by zippers and triggers. Trends Cell Biol 5: 89-93.
135. Owens, DE 3rd and Peppas, NA (2006). Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307: 93-102. (Pubitemid 41773257)
136. Vonarbourg, A, Passirani, C, Saulnier, P and Benoit, JP (2006). Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 27: 4356-4373. (Pubitemid 43674179)
137. Vachon, E, Martin, R, Plumb, J, Kwok, V, Vandivier, RW, Glogauer, M et al. (2006). CD44 is a phagocytic receptor. Blood 107: 4149-4158. (Pubitemid 43726826)
138. Gold, ES, Underhill, DM, Morrissette, NS, Guo, J, McNiven, MA and Aderem, A (1999). Dynamin 2 is required for phagocytosis in macrophages. J Exp Med 190: 1849-1856. (Pubitemid 30013850)
139. Claus, V, Jahraus, A, Tjelle, T, Berg, T, Kirschke, H, Faulstich, H et al. (1998). Lysosomal enzyme trafficking between phagosomes, endosomes, and lysosomes in J774 macrophages. Enrichment of cathepsin H in early endosomes. J Biol Chem 273: 9842-9851. (Pubitemid 28183080)
140. Racoosin, EL and Swanson, JA (1992). M-CSF-induced macropinocytosis increases solute endocytosis but not receptor-mediated endocytosis in mouse macrophages. J Cell Sci 102 (Pt 4): 867-880.
141. Strømhaug, PE, Berg, TO, Gjøen, T and Seglen, PO (1997). Differences between fluid-phase endocytosis (pinocytosis) and receptor-mediated endocytosis in isolated rat hepatocytes. Eur J Cell Biol 73: 28-39. (Pubitemid 27226188)
142. Swanson, JA and Watts, C (1995). Macropinocytosis. Trends Cell Biol 5: 424-428.
143. Conner, SD and Schmid, SL (2003). Regulated portals of entry into the cell. Nature 422: 37-44. (Pubitemid 36323287)
144. Mukherjee, S, Ghosh, RN and Maxfield, FR (1997). Endocytosis. Physiol Rev 77: 759-803. (Pubitemid 27328740)
145. Hillaireau, H and Couvreur, P (2009). Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66: 2873-2896.
146. Jones, AR and Shusta, EV (2007). Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res 24: 1759-1771. (Pubitemid 47206625)
147. Bareford, LM and Swaan, PW (2007). Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 59: 748-758. (Pubitemid 47320813)
148. Medina-Kauwe, LK (2007). "Alternative" endocytic mechanisms exploited by pathogens: new avenues for therapeutic delivery? Adv Drug Deliv Rev 59: 798-809. (Pubitemid 47320815)
149. Mayor, S and Pagano, RE (2007). Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 8: 603-612. (Pubitemid 47106613)
150. Marsh, M and Helenius, A (2006). Virus entry: open sesame. Cell 124: 729-740. (Pubitemid 43261448)
151. Yu, B, Zhao, X, Lee, LJ and Lee, RJ (2009). Targeted delivery systems for oligonucleotide therapeutics. AAPS J 11: 195-203.
152. Lu, JJ, Langer, R and Chen, J (2009). A novel mechanism is involved in cationic lipidmediated functional siRNA delivery. Mol Pharm 6: 763-771.
153. Boussif, O, Lezoualc'h, F, Zanta, MA, Mergny, MD, Scherman, D, Demeneix, B et al. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 92: 7297-7301.
154. Hafez, IM, Maurer, N and Cullis, PR (2001). On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther 8: 1188-1196. (Pubitemid 32776393)
155. Guo, X, MacKay, JA and Szoka, FC Jr (2003). Mechanism of pH-triggered collapse of phosphatidylethanolamine liposomes stabilized by an ortho ester polyethyleneglycol lipid. Biophys J 84: 1784-1795. (Pubitemid 36322940)
156. Endoh, T and Ohtsuki, T (2009). Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv Drug Deliv Rev 61: 704-709.
157. Dominska, M and Dykxhoorn, DM (2010). Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci 123(Pt 8): 1183-1189.
158. Jarad, G and Miner, JH (2009). Update on the glomerular filtration barrier. Curr Opin Nephrol Hypertens 18: 226-232.
159. Fogo, AB and Kon, V (2010). The glomerulus-a view from the inside-the endothelial cell. Int J Biochem Cell Biol 42: 1388-1397.
160. Miner, JH (2011). Glomerular basement membrane composition and the filtration barrier. Pediatr Nephrol 26: 1413-1417.
161. Patrakka, J and Tryggvason, K (2009). New insights into the role of podocytes in proteinuria. Nat Rev Nephrol 5: 463-468.
162. Wartiovaara, J, Ofverstedt, LG, Khoshnoodi, J, Zhang, J, Mäkelä, E, Sandin, S et al. (2004). Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. J Clin Invest 114: 1475-1483. (Pubitemid 40392426)
163. Rodewald, R and Karnovsky, MJ (1974). Porous substructure of the glomerular slit diaphragm in the rat and mouse. J Cell Biol 60: 423-433.
164. He, XM and Carter, DC (1992). Atomic structure and chemistry of human serum albumin. Nature 358: 209-215.
165. Patrakka, J and Tryggvason, K (2010). Molecular make-up of the glomerular filtration barrier. Biochem Biophys Res Commun 396: 164-169.
166. Kawachi, H, Miyauchi, N, Suzuki, K, Han, GD, Orikasa, M and Shimizu, F (2006). Role of podocyte slit diaphragm as a filtration barrier. Nephrology (Carlton) 11: 274-281. (Pubitemid 44086870)
167. Ghibellini, G, Leslie, EM and Brouwer, KL (2006). Methods to evaluate biliary excretion of drugs in humans: an updated review. Mol Pharm 3: 198-211.
168. Fleck, C and Bräunlich, H (1990). Factors determining the relationship between renal and hepatic excretion of xenobiotics. Arzneimittelforschung 40: 942-946. (Pubitemid 20241096)
169. Fagerholm, U (2008). Prediction of human pharmacokinetics-biliary and intestinal clearance and enterohepatic circulation. J Pharm Pharmacol 60: 535-542. (Pubitemid 351589043)
170. Huang, Y, Hong, J, Zheng, S, Ding, Y, Guo, S, Zhang, H et al. (2011). Elimination pathways of systemically delivered siRNA. Mol Ther 19: 381-385.